Travere Therapeutics Inc [TVTX] stock is trading at $20.31, down -2.40%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TVTX shares have gain 9.96% over the last week, with a monthly amount glided 18.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo upgraded its rating to Overweight on October 21, 2024, and elevated its price target to $27. On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. Guggenheim upgraded its rating to a Buy but stick to its price target of $25 on September 09, 2024. Guggenheim downgraded its rating to a Neutral. Citigroup upgraded its rating to Buy for this stock on December 05, 2023, and upped its price target to $10. In a note dated November 20, 2023, Citigroup initiated an Neutral rating and provided a target price of $7 on this stock.
Travere Therapeutics Inc [TVTX] stock has fluctuated between $5.12 and $20.89 over the past year. Currently, Wall Street analysts expect the stock to reach $21.75 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $20.31 at the most recent close of the market. An investor can expect a potential return of 7.09% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
Travere Therapeutics Inc [NASDAQ:TVTX] reported sales of 203.45M for the trailing twelve months, which represents a growth of 69.56%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -1.69%, Pretax Profit Margin comes in at -1.71%, and Net Profit Margin reading is -1.73%. To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -5.42 and Total Capital is -1.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-13.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.86 points at the first support level, and at 19.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.16, and for the 2nd resistance point, it is at 22.01.
Ratios To Look Out For
For context, Travere Therapeutics Inc’s Current Ratio is 1.71. Further, the Quick Ratio stands at 1.68, while the Cash Ratio is 0.19. Considering the valuation of this stock, the price to sales ratio is 8.69.
Transactions by insiders
Recent insider trading involved ROTE WILLIAM E., SENIOR VICE PRESIDENT, R&D, that happened on Jan 22 ’25 when 2437.0 shares were sold. CHIEF EXECUTIVE OFFICER, Dube Eric M completed a deal on Jan 22 ’25 to sell 10736.0 shares. Meanwhile, SVP, GC & CORPORATE SECRETARY REED ELIZABETH E sold 2437.0 shares on Jan 22 ’25.
